Pre-mRNA-splicing factor RBM22 (RBM22)

Pre-mRNA-splicing factor RBM22 is an essential RNA-binding protein involved primarily in pre-mRNA splicing and the regulation of gene expression[1][2][4]. It contains a zinc finger-like domain, a CCCH-type zinc finger, an RNA-recognition motif (RRM), and a proline-rich domain[1]. As a component of the activated spliceosome, RBM22 maintains the active conformation of the catalytic core by bridging interactions between snRNAs (such as U6) and spliceosomal proteins[1][4]. It also displays DNA-binding activity and can participate in transcription regulation, linking transcription and RNA processing machinery[1]. RBM22 is critical for cell survival, mitosis, and differentiation; mutations or misregulation are associated with cancer aggressiveness, myelodysplastic syndrome, and some neurodevelopmental disorders[1][2]. Although RBM22 is considered a potential anticancer therapeutic target due to its key role in splicing and gene regulation, no drugs are currently available that directly interact with RBM22, and validated biomarkers or mechanisms of action for RBM22-targeting drugs are not established[1][2].

Other names

ZC3H16fSAP47Cwc2 (yeast homolog)RNA binding motif protein 22Zinc finger CCCH domain-containing protein 16Functional spliceosome-associated protein 47FLJ10290199G4